Shares in Paion AG plunged by more than 65 percent Friday on news that the company's clot-busting stroke drug Desmoteplase failed to attain the primary endpoint in a placebo-controlled Phase III clinical trial in acute ischemic stroke. (BioWorld Today)
Shares in Paion AG plunged by more than 65 percent Friday on news that the company's clot-busting stroke drug Desmoteplase failed to attain the primary endpoint in a placebo-controlled Phase III clinical trial in acute ischemic stroke. (BioWorld Today)
Basel, Switzerland-based Basilea and its development partner, Johnson & Johnson, disclosed recently they had filed a new drug application for Ceftobiprole, a broad-spectrum cephalosporin antibiotic, for treatment of complicated skin and skin structure infection (cSSSI). A U.S. drug launch could follow early next year. (BioWorld International)
Basel, Switzerland-based Basilea and its development partner, Johnson & Johnson, disclosed recently they had filed a new drug application for Ceftobiprole, a broad-spectrum cephalosporin antibiotic, for treatment of complicated skin and skin structure infection (cSSSI). A U.S. drug launch could follow early next year. (BioWorld International)
